The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …

MicroRNAs (miRNAs) are gene regulators involved in the pathogenesis of complex
diseases such as cancers, and thus serve as potential diagnostic markers and therapeutic …

Liquid biopsy is an emerging technology with a potential role in the screening and early
detection of lung cancer. Several liquid biopsy-derived biomarkers have been identified and …

Cancer is also determined by the alterations of oncogenes and tumor suppressor genes.
These gene expressions can be regulated by microRNAs (miRNA). At this point, researchers …

Hepatocellular carcinoma (HCC) is one of the common malignant human tumors with high
morbidity worldwide. Aberrant activation of the oncogenic phosphoinositide 3‐kinase/protein …

Lung cancer (LC) causes the majority of cancer-related deaths. Circular RNAs (circRNAs)
were reported to play roles in cancers by targeting pro-and anti-oncogenic miRNAs …

Carcinoma of the lung is among the most common types of cancer globally. Concerning its
histology, it is categorized as a non-small cell carcinoma (NSCLC) and a small cell cancer …

Cancer is a leading cause of death worldwide, the early diagnosis of which decides the
patient's prognosis. The accurate sensing of tumor biomarkers is becoming one of the most …

The detection of biomarkers is critical for enabling early disease diagnosis, monitoring the
progression, and tracking the effectiveness of therapeutic intervention. Plasmonic sensors …

Liquid biopsy refers to the sampling, screening, and detecting potential biomarkers in
unique liquid samples for clinical use. Lung cancer is one of the most highly frequent cancer …